Axsome Therapeutics (AXSM) Inventory (2022 - 2026)

Axsome Therapeutics has disclosed Inventory across 5 years of filings, most recently posting $31.5 million for Q1 2026.

• Inventory for Q1 2026 came in at $31.5 million, up 93.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.5 million (up 93.12% YoY), and the FY2025 annual result was $27.9 million, up 77.59% from the prior year.
• Inventory came in at $31.5 million for Q1 2026 at Axsome Therapeutics, up from $27.9 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $31.5 million in Q1 2026 to a low of $4.3 million in Q4 2022.
• The 5-year median for Inventory is $15.2 million (2023), against an average of $15.6 million.
• Peak annual rise in Inventory reached 250.35% in 2023, while the deepest fall reached 28.62% in 2023.
• Axsome Therapeutics' Inventory stood at $4.3 million in 2022, then jumped by 250.35% to $15.1 million in 2023, then grew by 3.94% to $15.7 million in 2024, then soared by 77.59% to $27.9 million in 2025, then advanced by 12.8% to $31.5 million in 2026.
• The last three Inventory figures came in at $31.5 million (Q1 2026), $27.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.